Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 515

1.

Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.

Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R.

Immunotechnology. 1997 Mar;3(1):71-81.

PMID:
9154469
3.

A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing.

Roguska MA, Pedersen JT, Henry AH, Searle SM, Roja CM, Avery B, Hoffee M, Cook S, Lambert JM, Blättler WA, Rees AR, Guild BC.

Protein Eng. 1996 Oct;9(10):895-904. Erratum in: Protein Eng 1997 Feb;10(2):181.

PMID:
8931129
4.

Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.

Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM.

Protein Eng. 1991 Oct;4(7):773-83.

PMID:
1798701
5.

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

Wu H, Nie Y, Huse WD, Watkins JD.

J Mol Biol. 1999 Nov 19;294(1):151-62.

PMID:
10556035
6.

Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.

Sato K, Ohtomo T, Hirata Y, Saito H, Matsuura T, Akimoto T, Akamatsu K, Koishihara Y, Ohsugi Y, Tsuchiya M.

Hum Antibodies Hybridomas. 1996;7(4):175-83.

PMID:
9140729
7.

Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.

De Pascalis R, Iwahashi M, Tamura M, Padlan EA, Gonzales NR, Santos AD, Giuliano M, Schuck P, Schlom J, Kashmiri SV.

J Immunol. 2002 Sep 15;169(6):3076-84.

8.

Antibody humanization by framework shuffling.

Dall'Acqua WF, Damschroder MM, Zhang J, Woods RM, Widjaja L, Yu J, Wu H.

Methods. 2005 May;36(1):43-60.

PMID:
15848074
9.

Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528.

Makabe K, Nakanishi T, Tsumoto K, Tanaka Y, Kondo H, Umetsu M, Sone Y, Asano R, Kumagai I.

J Biol Chem. 2008 Jan 11;283(2):1156-66. Epub 2007 Oct 17.

10.

Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.

Staelens S, Desmet J, Ngo TH, Vauterin S, Pareyn I, Barbeaux P, Van Rompaey I, Stassen JM, Deckmyn H, Vanhoorelbeke K.

Mol Immunol. 2006 Mar;43(8):1243-57. Epub 2005 Aug 22.

PMID:
16118019
11.

Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies.

Kolbinger F, Saldanha J, Hardman N, Bendig MM.

Protein Eng. 1993 Nov;6(8):971-80.

PMID:
8309946
12.

The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.

Giles I, Lambrianides N, Latchman D, Chen P, Chukwuocha R, Isenberg D, Rahman A.

Arthritis Res Ther. 2005;7(1):R47-56. Epub 2004 Nov 16.

13.

Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.

Boado RJ, Zhang Y, Zhang Y, Pardridge WM.

Biotechnol Bioeng. 2007 Feb 1;96(2):381-91.

PMID:
16937408
14.

Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions.

Ohtomo T, Tsuchiya M, Sato K, Shimizu K, Moriuchi S, Miyao Y, Akimoto T, Akamatsu K, Hayakawa T, Ohsugi Y.

Mol Immunol. 1995 Apr;32(6):407-16.

PMID:
7753049
15.

Humanization of an anti-p185HER2 antibody for human cancer therapy.

Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM.

Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9.

16.

A humanized antibody that binds to the interleukin 2 receptor.

Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA.

Proc Natl Acad Sci U S A. 1989 Dec;86(24):10029-33.

17.

Expression and characterization of a mouse/human chimeric antibody specific for EGF receptor.

Ferrer C, Anastasi AM, Di Massimo AM, Bullo A, Di Loreto M, Raucci G, Pacilli A, Rotondaro L, Mauro S, Mele A, De Santis R.

J Biotechnol. 1996 Nov 29;52(1):51-60.

PMID:
9025323
18.

Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody.

Nakamura K, Tanaka Y, Fujino I, Hirayama N, Shitara K, Hanai N.

Mol Immunol. 2000 Dec;37(17):1035-46.

PMID:
11399321
19.
20.

Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha).

Nagahira K, Fukuda Y, Oyama Y, Kurihara T, Nasu T, Kawashima H, Noguchi C, Oikawa S, Nakanishi T.

J Immunol Methods. 1999 Jan 1;222(1-2):83-92.

PMID:
10022375

Supplemental Content

Support Center